Investment Thesis
GRI Bio is a pre-revenue pharmaceutical company burning $3.7M annually with only $16K in revenue and -$2M operating losses. Despite $11M in cash reserves, the current burn rate depletes runway in approximately 3 years without revenue inflection or capital restructuring. Fundamental business model shows no traction and unacceptable operational risk.
Strengths
- Strong liquidity position with $11M cash equivalents representing 14.21x current ratio coverage
- Zero debt burden eliminates financial stress and provides capital structure flexibility
- Minimal capex requirements ($3K) and conservative balance sheet operation
Risks
- Pre-revenue stage with $16K revenue against $3.7M annual operating cash burn creating urgent solvency timeline
- Operating margin of -12,518.8% indicates fundamental business model execution failure
- No disclosed pipeline visibility, clinical trial progress, or commercialization milestones create uncertainty on capital deployment
- Imminent cash depletion within 3 years necessitates dilutive capital raise or asset sale
- Zero Form 4 insider filings suggest complete lack of insider confidence in company direction
Key Metrics to Watch
- Quarterly revenue growth trajectory and acceleration toward commercial break-even
- Monthly cash burn rate trend and cash runway extension announcements
- FDA clinical trial milestone achievements and drug pipeline advancement disclosures
- Capital raise announcements and dilution impact on equity holders
- Operating cash flow improvement and path to positive cash generation
Financial Metrics
Revenue
16.0K
Net Income
-2.0M
EPS (Diluted)
$-1.61
Free Cash Flow
-3.7M
Total Assets
11.3M
Cash
11.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-12,518.8%
Net Margin
-12,487.5%
ROE
-18.9%
ROA
-17.6%
FCF Margin
-23,050.0%
Balance Sheet & Liquidity
Current Ratio
14.21x
Quick Ratio
14.21x
Debt/Equity
0.00x
Debt/Assets
7.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:24:45.048187 |
Data as of: 2026-03-31 |
Powered by Claude AI